Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study

被引：0
|
作者：
Aran Kim
Yunkyung Kim
Geun-Tae Kim
Eunyoung Ahn
Min Wook So
Seung-Geun Lee
机构：
[1] Pusan National University Hospital,Division of Rheumatology, Department of Internal Medicine
[2] Pusan National University School of Medicine,Biomedical Research Institute
[3] Pusan National University Hospital,Division of Rheumatology, Department of Internal Medicine
[4] Kosin University College of Medicine,Division of Rheumatology, Department of Internal Medicine
[5] Pusan National University Yangsan Hospital,undefined
来源：
Clinical Rheumatology | 2020年 / 39卷
关键词：
Allopurinol; Febuxostat; Gout; Medication adherence; Patient compliance; Uric acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3769 / 3776
页数：7
相关论文
共 50 条
  • [41] Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factore-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
    Vaz-Luis, Ines
    Seah, Davinia
    Olson, Erin M.
    Wagle, Nikhil
    Metzger-Filho, Otto
    Sohl, Jessica
    Litsas, Georgia
    Burstein, Harold J.
    Krop, Ian E.
    Winer, Eric P.
    Lin, Nancy U.
    CLINICAL BREAST CANCER, 2013, 13 (04) : 254 - 263
  • [42] Predictors of Loss to Follow-Up among HIV-Infected Adults after Initiation of the First-Line Antiretroviral Therapy at Arba Minch General Hospital, Southern Ethiopia: A 5-Year Retrospective Cohort Study
    Gebremichael, Mathewos Alemu
    Gurara, Mekdes Kondale
    Weldehawaryat, Haymanot Nigussie
    Mengesha, Melkamu Merid
    Berbada, Dessalegn Ajema
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [43] THE RETENTION RATE OF ETANERCEPT AND ADALIMUMAB IN FIRST-LINE AND AFTER NON-MEDICAL SWITCH IN PATIENTS WITH PSORIATIC ARTHRITIS: A COMPARISON BETWEEN ORIGINATORS AND BIOSIMILARS. A SINGLE-CENTER RETROSPECTIVE STUDY.
    Hannech, E.
    Miladi, S.
    Fazaa, A.
    Boussaa, H.
    Yasmine, M.
    Souabni, L.
    Ouenniche, K.
    Kassab, S.
    Chekili, S.
    Ben Abdelghani, K.
    Laatar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1794 - 1794
  • [44] THE RETENTION RATE OF ETANERCEPT AND ADALIMUMAB IN FIRST-LINE AND AFTER NON-MEDICAL SWITCH IN PATIENTS WITH PSORIATIC ARTHRITIS: A COMPARISON BETWEEN ORIGINATORS AND BIOSIMILARS. A SINGLE-CENTER RETROSPECTIVE STUDY.
    Rella, V.
    Rotondo, C.
    Maruotti, N.
    Altomare, A.
    Erroi, F.
    Stefania, S.
    Trotta, A.
    Cantatore, F. P.
    Corrado, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1794 - 1794
  • [45] COMPARISON BETWEEN TIME-DEPENDENT COX AND MARGINAL STRUCTURAL MODELING APPROACHES TO ESTIMATING THE EFFECT OF PRESCRIPTION COST-SHARING ON PERSISTENCE WITH FIRST-LINE ANTIRETROVIRAL THERAPY AMONG TREATMENT ANTIRETROVIRAL-NAIVE HIV PATIENTS
    Chu, B. C.
    Johnston, S. S.
    Juneau, P.
    Juday, T.
    VALUE IN HEALTH, 2013, 16 (03) : A47 - A47
  • [46] HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
    Carlino, Francesca
    Diana, Anna
    Ventriglia, Anna
    Piccolo, Antonio
    Mocerino, Carmela
    Riccardi, Ferdinando
    Bilancia, Domenico
    Giotta, Francesco
    Antoniol, Giulio
    Famiglietti, Vincenzo
    Feliciano, Salvatore
    Cangiano, Rodolfo
    Lobianco, Lorenzo
    Pellegrino, Benedetta
    De Vita, Ferdinando
    Ciardiello, Fortunato
    Orditura, Michele
    CANCERS, 2022, 14 (20)
  • [47] Clinical outcomes in non-small cell lung cancer patients with ultra-high expression of programmed death ligand-1 treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study
    Kurebe, H.
    Edahiro, R.
    Kanazu, M.
    Fujimoto, D.
    Tamiya, M.
    Tamiya, A.
    Suzuki, H.
    Hirano, K.
    Yokoyama, T.
    Morita, M.
    Fukuda, Y.
    Uchida, J.
    Makio, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study
    Cesas, Alvydas
    Urbonas, Vincas
    Tulyte, Skaiste
    Janciauskiene, Rasa
    Liutkauskiene, Sigita
    Grabauskyte, Ingrida
    Gaidamavicius, Ignas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 6979 - 6988
  • [49] Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Poggio, Francesca
    Puglisi, Fabio
    Bernardo, Antonio
    Montemurro, Filippo
    Poletto, Elena
    Pozzi, Emma
    Rossi, Valentina
    Risi, Emanuela
    Lai, Antonella
    Zanardi, Elisa
    Sini, Valentina
    Ziliani, Serena
    Minuti, Gabriele
    Mura, Silvia
    Grasso, Donatella
    Fontana, Andrea
    Del Mastro, Lucia
    ONCOLOGIST, 2015, 20 (08): : 880 - 889
  • [50] Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Takashi Ikeda
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2023, 18 : 209 - 220
12345